Scopolamine is an anticholinergic alkaloid which acts as a competitive, reversible inhibitor of muscarinic acetylcholine receptors in the heart and central nervous system. It is mainly used for the treatment of motion sickness, nausea, vomiting and other gastrointestinal disorders. Scopolamine API is used as an active pharmaceutical ingredient in manufacturing pharmaceutical formulations used for prevention and treatment of motion sickness symptoms of nausea and vomiting.

The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
The growing awareness about motion sickness and its prevention provides a huge market opportunity for Scopolamine API. Motion sickness is a very common condition affecting nearly 50% of population. It occurs due to conflicting signals received by brain and inner ear during traveling by road, sea or air. As the global travel and tourism industry is witnessing high growth, there is increasing demand for effective motion sickness prevention and treatment options. This increases the utilization of Scopolamine formulations and thus drives the growth of Scopolamine API market.

Porter's Analysis

Threat of new entrants: The scopolamine API market is highly regulated and the substantial capital required to enter the market poses barriers for new companies.

Bargaining power of buyers: The buyers have moderate to low bargaining power as there are numerous established suppliers offering scopolamine API.

Bargaining power of suppliers: The suppliers have moderate bargaining power due to the differentiated nature of their products and formulations.

Threat of new substitutes: There are few product substitutes for scopolamine API available currently.

Competitive rivalry: The competitive rivalry is high among the major players.

SWOT Analysis

Strength: Established production facilities and efficient supply chain management. Cost-effective commercialization of niche products.

Weakness: High R&D costs for new product development. Stringent regulatory norms hamper product approvals.

Opportunity: Growing incidence of motion sickness provides potential for market growth. Advancements in pharmaceutical drug delivery systems offer new areas.

Threats: Price fluctuations of raw materials impact production costs. Patent expiries of major drugs lead to higher competition.

Key Takeaways

The global Scopolamine API Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The global scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030.

Regional analysis for Asia Pacific comprises the region holding the largest share of over 35% of the global scopolamine API market in 2023. Expansion of existing manufacturing units and investments in new facilities by key players such as Daikin Industries are driving the market growth.

Key players related content comprises Key players operating in the scopolamine API market are Daikin Industries Limited, Viessmann Group, NIBE Group, Danfoss Group Global, Stiebel Eltron Group, Mitsubishi Electric Corporation, United Technologies Corporation, Panasonic Corporation, Glen Dimplex Group, and The Bosch Group. Daikin Industries is one of the leading suppliers with a broad product portfolio and global manufacturing presence.

For more insights, read- https://www.newsanalyticspro.com/scopolamine-api-market-trends-size-and-share-analysis/